Envafolimab plus chemotherapy before surgery for stage IIb bone cancer
Part of Cancer clinical trials.
This trial tests a new drug, envafolimab, combined with chemotherapy before surgery for patients with a type of bone cancer called osteosarcoma that has not spread. The goal is to see if this approach can improve the chance of removing the tumor successfully and reducing the risk of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You have been diagnosed with osteosarcoma (a type of bone cancer) that can be removed with surgery and has not spread to other parts of the body.
- You have not had any previous treatment for this cancer.
- You are in generally good health (able to carry out daily activities) and your organ function (like blood, liver, and kidneys) is adequate.
- You do not have other serious illnesses or conditions (like active autoimmune disease, heart problems, or infections) that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests if adding the immunotherapy drug sugemalimab to standard chemotherapy before and after surgery can help people with stage II-IIIA non-small cell lung cancer. It aims to see if this combination reduces the chance of cancer coming back.
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.